Can you make semaglutide, and how is it actually produced?

What making semaglutide actually involves, and why it can't be done at home

Semaglutide is a GLP-1 receptor agonist built from a chain of 31 amino acids, structurally modified so that it resists the enzymes that would normally break it down quickly in the body. That modification (attaching a fatty acid chain to the peptide backbone) is what gives it the long half-life needed for once-weekly dosing. Producing it requires solid-phase peptide synthesis carried out in pharmaceutical-grade manufacturing plants, followed by purification steps, quality testing and sterile fill-finish in injection pens or tablet formulations. There is no equivalent of a home chemistry kit for this process. The equipment involved is industrial; the quality standards required under Good Manufacturing Practice run to thousands of pages of regulation.

Questions about how to make semaglutide sometimes arise from curiosity about the medicine's origins, and sometimes from frustration with access and cost. Both are understandable. The molecule itself has a genuinely fascinating history, if you are curious about the biological pathway it mimics, our page on semaglutide's origins and the GLP-1 hormone covers the science in detail. The key practical point is that licensed Wegovy, produced by Novo Nordisk and dispensed through a registered UK pharmacy, is the only form of semaglutide that has been through the clinical trials, quality testing and MHRA approval process needed to confirm it is safe and effective for weight management.

The risks of attempting to source or make your own semaglutide extend well beyond legality, unlicensed preparations have no verified dose, no confirmed purity and no stability data.

Why the licensed supply chain exists, and what happens outside it

Novo Nordisk manufactures semaglutide at scale and supplies it to the UK through an MHRA-authorised distribution chain. A GPhC-registered pharmacy must verify the product's provenance, store it correctly (refrigerated between 2–8°C before first use, the kind of thing you manage by keeping your pen in the fridge door rather than in a bag left in a warm car) and dispense it only against a valid prescription from a registered prescriber. That chain of custody exists because the consequences of counterfeit or degraded product are serious.

The MHRA has issued repeated public warnings about fake weight-loss pens sold online. In October 2023 the agency flagged counterfeit pens (some containing insulin rather than semaglutide) that had reached patients and caused hospitalisations. By 2025, enforcement had escalated to seizures of roughly 20 million doses of illegally traded weight-loss medicines, worth around £45 million. Those figures are not abstract: they reflect a market of sellers willing to put something in an official-looking pen without concern for what it actually contains. You can report suspected counterfeit products directly via the MHRA's Yellow Card scheme.

For anyone thinking about cost as the driver behind the question, our guide to Wegovy pricing in the UK explains what legitimate treatment actually costs and what to read into prices that seem unusually low.

The decision: licensed treatment through a registered prescriber, or nothing

If the underlying question is whether you can access semaglutide for weight management, the answer in the UK is yes, through a licensed route. Wegovy is approved by the MHRA for adults with a BMI of 30 or above, or 27 or above where a weight-related condition such as high blood pressure or high cholesterol is present. A prescriber reviews your medical history, current medicines and circumstances before deciding whether treatment is clinically appropriate. That assessment also matters because semaglutide is not suitable for everyone: people who are pregnant, breastfeeding or trying to conceive should not use it, and it is not licensed for anyone under 18. Certain medical histories (including a personal or family history of medullary thyroid carcinoma) require careful prescriber discussion.

The NHS provides clear patient-level information on semaglutide, including how it works and what side effects to be aware of. A prescriber's involvement is not a bureaucratic hurdle; it is the step that makes the treatment safe and legal, and the step that connects you to a product whose contents, dose and stability you can actually rely on. If you would like to explore whether Wegovy is clinically suitable for you, our prescribers review consultations the same day, a real clinician reads your answers, not an automated system.

You can also find broader information about Wegovy and how it is used for weight management, or read through who semaglutide is and isn't suitable for before you decide whether to go ahead. Our weight loss treatment overview sets out all the options available through nume in one place.